Biotechnology company developing recombinant human collagen type VII (rC7), a protein replacement therapy for dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder
Biotechnology company developing recombinant human collagen type VII (rC7), a protein replacement therapy for dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. Founded in 2011 in Cambridge, Massachusetts, it was acquired by Shire in 2015.